Lower ghrelin levels does not impact the metabolic benefit induced by Roux-en-Y gastric bypass

Front Endocrinol (Lausanne). 2022 Aug 23:13:891379. doi: 10.3389/fendo.2022.891379. eCollection 2022.

Abstract

Objective: Roux-en-Y gastric bypass is an effective intervention for metabolic disorder. We aim to elucidate whether ghrelin contributes to weight reduction, and glycemic and lipid control after Roux-en-Y gastric bypass (RYGB).

Design: Four-week-old WT and Ghrl-TSC1-/- mice were fed high fat diet for 12 weeks before surgery, and continued to be on the same diet for 3 weeks after surgery. Body weight, food intake, glycemic and lipid metabolism were analyzed before and after surgery.

Results: Gastric and circulating ghrelin was significantly increased in mice with RYGB surgery. Hypoghrelinemia elicited by deletion of TSC1 to activate mTOR signaling in gastric X/A like cells demonstrated no effect on weight reduction, glycemic and lipid control induced by Roux-en-Y gastric bypass surgery.

Conclusion: Lower ghrelin levels does not impact the metabolic benefit induced by Roux-en-Y gastric bypass.

Keywords: Roux-en-Y gastric bypass; body weight; ghrelin; glucose metabolism; lipid metabolism.

MeSH terms

  • Animals
  • Blood Glucose / metabolism
  • Diet, High-Fat
  • Gastric Bypass*
  • Ghrelin* / blood
  • Ghrelin* / chemistry
  • Lipids
  • Mice
  • Weight Loss / physiology

Substances

  • Blood Glucose
  • Ghrelin
  • Lipids